Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In the pivotal trials, tirzepatide 15 mg achieved 22.5 percent body weight in obesity alone (SURMOUNT-1) and clearly outperformed semaglutide head to head on diabetes weight loss (SURPASS-2)
Most patients find this significantly more affordable than brand-name Mounjaro, with no insurance requirement, no membership fees, and HSA/FSA eligibility available
He said this prevents the company for having a durable offering of branded weight-loss drugs at scale
Indirect evidence showed overall superiority over DPP-4 inhibitors, which appears to be a class effect.16,17 However, superiority between GLP-1 RAs and SGLT2 inhibitors varies across different outcomes
